By Yoon Hang "John" Kim, MD, MPH

There is a phrase that has followed myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) for decades: diagnosis of exclusion. Taken too literally, it implies that clinicians arrive at ME/CFS only after exhausting every other possibility — as though the diagnosis is simply what remains when nothing else fits.

That is not the best way to approach the illness.

ME/CFS has no confirmatory laboratory test, and clinicians must appropriately evaluate other conditions that could explain or contribute to the presentation. But ME/CFS is also a recognizable clinical syndrome defined by positive features — particularly post-exertional malaise (PEM), substantial loss of function, unrefreshing sleep, and cognitive impairment and/or orthostatic intolerance.

The better model is therefore syndrome recognition paired with a targeted differential diagnosis, not endless testing until everything else has been ruled out.

The 2015 IOM/NAM Framework: Why It Matters

In 2015, the Institute of Medicine (IOM, now the National Academy of Medicine) proposed evidence-informed consensus criteria for ME/CFS. These criteria are currently presented by the CDC as the practical U.S. clinical framework.

Diagnosis requires all three required features plus at least one of two additional manifestations.

Required features:

1. Substantial reduction or impairment in function accompanied by fatigue. The patient has a meaningful reduction in the ability to engage in pre-illness occupational, educational, social, or personal activities lasting more than six months. The accompanying fatigue is often profound, is of new or definite onset rather than lifelong, is not caused by ongoing excessive exertion, and is not substantially relieved by rest.
2. Post-exertional malaise. Symptoms worsen following physical, cognitive, emotional, or other exertion that previously would not have caused difficulty. The worsening is often delayed; the CDC notes that symptoms typically become more pronounced 12 to 48 hours later and may persist for days or weeks.
3. Unrefreshing sleep. Sleep does not restore function or meaningfully improve the patient's condition, even when sleep duration appears adequate.

At least one additional manifestation is required:

• Cognitive impairment — including difficulty with concentration, information processing, working memory, executive function, or word retrieval.
• Orthostatic intolerance — symptoms that worsen with maintaining an upright posture and improve, at least partially, with recumbency.

For PEM, unrefreshing sleep, and cognitive impairment specifically, the IOM recommends assessing frequency and severity: the diagnosis should be questioned when these symptoms are not present at least half the time with at least moderate intensity.

PEM Is the Hallmark — So Take the History Carefully

If there is one clinical pearl to carry away from ME/CFS diagnosis, it is this: phenotype the post-exertional malaise carefully.

PEM is not simply "being tired after doing things." It is a disproportionate worsening of the patient's overall illness following exertion that would previously have been tolerated. Although PEM is not unique to ME/CFS — it also occurs prominently in Long COVID and some other post-infectious syndromes — it remains the feature that most clearly separates ME/CFS from ordinary fatigue.

When taking the history, consider four dimensions.

Identify the trigger threshold. Physical activity is the most obvious trigger, but cognitive effort, emotional exertion, and sensory overload can also precipitate symptom worsening. Prolonged upright activity may contribute, particularly in patients with coexisting orthostatic intolerance.

Clarify the timing. PEM is often delayed. A patient can feel relatively acceptable during or immediately after an activity and experience the full consequence later. Asking, “How do you feel later that day or the next day?” is frequently more revealing than asking only how the patient felt immediately afterward.

Characterize the symptom pattern. PEM often involves more than fatigue: cognitive dysfunction, myalgias, headache, sleep disruption, flu-like malaise, sore throat, sensory sensitivity, and worsening autonomic symptoms may all appear together.

Establish recovery time. Recovery can require days and, after more significant exacerbations, sometimes weeks or longer. The prolonged recovery distinguishes PEM from ordinary post-exercise tiredness.

A typical history: a previously active patient completes a routine shopping trip or an hour of concentrated desk work. They feel reasonably well at the time but develop marked cognitive slowing, myalgias, tachycardia, sore throat, and profoundly nonrestorative sleep the following day, followed by several days of reduced function. That delayed, multisystem, disproportionate response is far more diagnostically informative than the word fatigue alone.

Cognitive Impairment and Orthostatic Intolerance

Cognitive impairment in ME/CFS extends beyond the vague concept of “brain fog.” Patients may experience slowed information processing, impaired attention, reduced working memory, difficulty multitasking, diminished verbal fluency, and word-retrieval problems. Symptoms often worsen with exertion, prolonged upright posture, sensory stimulation, stress, or time pressure.

Orthostatic intolerance is also frequently overlooked. Symptoms worsen during standing — and in some patients during prolonged upright sitting — and improve with lying down. Manifestations include lightheadedness, presyncope or syncope, palpitations, tachycardia, nausea, headache, tremulousness, fatigue, and worsening cognition.

When indicated, office assessment can include a standardized standing protocol such as a 10-minute NASA Lean Test with serial heart rate, blood pressure, and symptom monitoring. Formal tilt-table testing may be considered when clinically appropriate.

A Word on Competing Criteria

The IOM/NAM criteria are not the only diagnostic framework in use.

The Canadian Consensus Criteria (CCC, 2003) describe a broader multisystem phenotype and require fatigue, PEM/post-exertional fatigue, sleep dysfunction, pain, neurologic/cognitive manifestations, and symptoms across autonomic, neuroendocrine, and immune domains.

The International Consensus Criteria (ICC, 2011) use the term post-exertional neuroimmune exhaustion and require a more symptom-dense combination of neurologic, immune/gastrointestinal/genitourinary, and energy-production or transport manifestations. Comparative studies suggest that ICC generally identifies a smaller, more symptomatically impaired subgroup.

The older Fukuda 1994 research definition remains historically important but does not require PEM. It can therefore identify a broader and more heterogeneous population than contemporary definitions that treat PEM as a required feature.

For routine U.S. clinical practice, the IOM/NAM framework is the most straightforward starting point. CCC or ICC features can then be used to further phenotype the patient when clinically useful.

The Diagnostic Work-Up: Targeted, Not Exhaustive

ME/CFS does not require every conceivable laboratory test to be normal before the diagnosis can be considered. At the same time, the presence of a recognizable ME/CFS phenotype should not lead to premature diagnostic closure.

The goal is a targeted evaluation for disorders that could explain or materially contribute to the presentation.

A reasonable baseline evaluation typically includes a CBC with differential, inflammatory markers (ESR and CRP), electrolytes, glucose assessment, renal and hepatic function, calcium and phosphate, thyroid studies, iron studies including ferritin, celiac screening, and urinalysis. Additional testing should be driven by the patient's history, examination, and specific abnormalities rather than ordered indiscriminately — the CDC specifically cautions that extensive nonselective testing generates false positives that can lead to misdiagnosis.

Important considerations include sleep disorders such as obstructive sleep apnea, circadian disorders, restless legs syndrome, and periodic limb movements; endocrine and metabolic disease; anemia and nutritional deficiencies; autoimmune, inflammatory, infectious, neurologic, cardiopulmonary, renal, hepatic, and malignant disease when clinically indicated; and medication or substance effects, particularly sedating agents.

Depression and anxiety also deserve appropriate evaluation and treatment, and they can coexist with ME/CFS. A mood disorder alone, however, should not be presumed to explain a characteristic pattern of delayed PEM or documented orthostatic abnormalities.

Comorbidities Are Not Automatically Competing Diagnoses

An important distinction: a competing diagnosis is one that could account for the entire clinical picture; a coexisting condition is one that travels alongside ME/CFS without displacing it.

Orthostatic intolerance and POTS, fibromyalgia, migraine and chronic headache, irritable bowel syndrome, and other chronic pain conditions are frequently encountered in patients with ME/CFS. Hypermobility disorders and mast-cell activation phenotypes have also been reported in overlapping patient populations, although the evidence regarding their prevalence and relationship to ME/CFS continues to evolve.

The presence of such conditions neither establishes nor excludes ME/CFS. Each should be evaluated on its own merits while asking the more important question: Does it adequately explain the patient's entire clinical syndrome, including the characteristic PEM pattern?

Additional symptoms such as myalgia, arthralgia, headache, sore throat, tender lymph nodes, temperature dysregulation, gastrointestinal complaints, sensory hypersensitivity, and sensitivities to foods, odors, chemicals, or medications may fit the ME/CFS phenotype but are not independently diagnostic.

Documentation: Say It Clearly

Clear documentation improves continuity of care and helps subsequent clinicians understand why the diagnosis was made.

A useful diagnostic statement might read:

Patient meets 2015 IOM/NAM clinical criteria for ME/CFS: substantial reduction in pre-illness functional capacity for more than six months accompanied by new-onset fatigue not substantially relieved by rest; characteristic post-exertional malaise; unrefreshing sleep; and cognitive impairment and/or orthostatic intolerance. Appropriate evaluation for alternative and contributing conditions has been undertaken.

Documentation should describe the patient's premorbid versus current functional capacity, the trigger-delay-duration pattern of PEM, sleep quality, cognitive and orthostatic manifestations, symptom frequency and severity, relevant objective findings, and the reasoning used in evaluating alternative or comorbid diagnoses.

Closing Thoughts

The choice is not between recognizing ME/CFS clinically and evaluating other diseases. Good diagnosis requires both.

ME/CFS is a recognizable clinical syndrome, but there is currently no confirmatory diagnostic test. The 2015 IOM/NAM criteria provide a practical, evidence-informed consensus framework centered on the features most characteristic of the illness — particularly PEM.

Clinicians can and should begin considering ME/CFS early in the course of an appropriate illness and evaluate alternative explanations concurrently. Under the IOM/NAM framework, formal diagnosis is made once the required duration criterion has been met.

The goal is neither premature diagnostic closure nor years of diagnostic wandering. It is careful recognition of the clinical pattern, a rational differential diagnosis, and timely, well-documented care.

References

1. Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press; 2015. doi:10.17226/19012.
2. Centers for Disease Control and Prevention. IOM 2015 Diagnostic Criteria for ME/CFS. https://www.cdc.gov/me-cfs/hcp/diagnosis/iom-2015-diagnostic-criteria-1.html
3. Centers for Disease Control and Prevention. Evaluation of ME/CFS. Updated April 17, 2026. https://www.cdc.gov/me-cfs/hcp/diagnosis-testing/evaluation-of-me-cfs.html
4. Bateman L, Bested AC, Bonilla HF, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: essentials of diagnosis and management. Mayo Clin Proc. 2021;96(11):2861-2878. doi:10.1016/j.mayocp.2021.07.004.
5. Carruthers BM, Jain AK, De Meirleir KL, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr. 2003;11(1):7-115. doi:10.1300/J092v11n01_02.
6. Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011;270(4):327-338. doi:10.1111/j.1365-2796.2011.02428.x.
7. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121(12):953-959. doi:10.7326/0003-4819-121-12-199412150-00009.
8. Conroy KE, Islam MF, Jason LA. Evaluating case diagnostic criteria for ME/CFS: toward an empirical case definition. Disabil Rehabil. 2023;45(5):840-847. doi:10.1080/09638288.2022.2043462.